Ignyta Investor Information

Ignyta, Inc. is writing a new story for cancer treatment, a story that features our distinctive Rx/Dx strategy to blaze a new path forward for patients.

Physicians discussing a patient chart

Our integrated approach combines precision therapeutics with companion molecular diagnostics for the potential benefit of patients with cancer.

Our people work daily to develop meaningful new drugs that target the molecular abnormalities of cancer, allowing us to advance precision therapies to treat each patient’s specific cancer.

We endeavor to eradicate residual disease in precisely defined patient populations by 2030, an audacious goal – backed by the unique combination of delivering the next generation of targeted therapeutics, accompanied by highly informative biomarkers for patient selection, treatment, and monitoring – that makes us confident we can help write the next chapter in the ever-changing story of cancer care.

To stay up to date on all Ignyta investor information, including Press Releases, Stock Information, SEC filings, and more, sign up for Ignyta email alerts.

Ignyta, Inc. (Nasdaq: RXDX) stock information, including a current stock ticker and historical trending.

View Stock Info

A sortable database of downloadable Ignyta, Inc. Press Releases from 2012 to present in PDF format.

Read Press Releases

A sortable database of Ignyta, Inc. SEC filings for all years 2013 to present, in HTML, PDF, and XLS formats.

View SEC Filings

Ignyta Events & Presentations

As a leader in biotechnology and precision medicine, the Ignyta team frequently presents at industry conferences and events, including clinical data, information on Ignyta clinical trials, and breakthroughs in the evolution of cancer treatment.

View Upcoming Events
Speaker in front of large group of people

Stock Information

Table scrolls to the right >>

8.95
current stock price
4 PM ET | Apr 25, 2017
Previous Close 8.95 Day High 0.00
Open 0.00 Day Low 0.00
Volume 0 52-Week High 9.90
Exchange NASDAQ 52-Week Low 4.15

Press Releases

Apr 24, 2017 Ignyta to Host Conference Call and Webcast Update on Entrectinib Program and STARTRK-2 on April 27, 2017
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq:RXDX), a biotechnology company focused on precision medicine in oncology, today announced that Ignyta management will host a conference call and live webcast on April 27, 2017, at 1:30 PM Pacific time (4:30 PM Eas
Apr 04, 2017 Ignyta Announces New Data Highlighting Broad Potential of Both RXDX-106 and Entrectinib at the 2017 AACR Annual Meeting
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, today announced that preclinical data on RXDX-106 - which represents a novel class of immunomodulatory agents that appears to restore inna
Mar 30, 2017 Ignyta Announces Peer-Reviewed Publication of Activity of a TRK Inhibitor in a Primary Brain Tumor: Successful Treatment of Glioneuronal Tumor With Pan-TRK, CNS-Active Inhibitor Entrectinib Published in Precision Oncology
Study found three NTRK fusions within cohort of 26 glioneuronal tumors One patient with an NTRK1 fusion was treated with entrectinib, resulting in 60% tumor regression and resolution of clinical symptoms that was maintained for 11 months on treatme